24-h Arteriograph ® Central BP

4. Laboratory investigations (WP4): fasting plasma glucose, lipids, serum creatinine, serum liver enzymes, biomarkers (for inflammation, copeptin, etc., see Table 1), urinary spot sample for microalbuminuria and albumin/creatinine ratio. In addition, faeces samples will be obtained for determination of secreted factors as well as a genetic screening for evaluation of the gut bacterial content and composition (microbiota). A biobank will be established in technical collaboration between Lund University and other partners (Region Skåne, BBMRI.se). Assessment of leukocyte types and activation in whole blood will be performed in representative subsets of subjects. 5. Metabolic investigation (WP5): including fasting blood sampling for plasma glucose and serum lipids (total cholesterol: C, HDL-C, LDL-C and triglycerides, LpLA2, Lp(a), etc.), and an oral glucose tolerance test (OGTT; 75 g glucose), with measurements at 0,30,(60) and 120 min of plasma glucose, incretins (GLP-1, GIP), insulin, C-peptide and glucagon. 6. Technical investigations (WP6): arterial stiffness (Sphygmocor ® assessment of pulse wave velocity, augmentation index, central blood pressure), arteria carotis morphology and function (Sekoya ® ultrasound device), 24-h ambulatory blood pressure recordings, and central aortic pressure (24-h Arteriograph ® Central BP). We will perform screening spirometry and evaluation of endothelial function (by EndoPat ®).Measurement of Advanced Glycation End Products (AGE) will be conducted transdermally by use of an AGE-Reader®. In addition, other investigations are optional and depending on funding, such as brain magnetic resonance imaging (MRI) as well as echocardiography, and retinal artery imaging